Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

NCT05952037 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05952037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05952037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Lead sponsor
BeOne Medicines
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 23, 2023
Completion date
August 31, 2028
Enrollment
114 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia, waldenstrom's macroglobulinemia recurrent, waldenstrom's macroglobulinemia refractory